With over 4.81 million Taysha Gene Therapies Inc. (TSHA) shares trading Tuesday and a closing price of $3.02 on the day, the dollar volume was approximately $14.51 million. The shares have shown a positive half year performance of 220.22% and its price on 09/12/23 lost nearly -13.71%. Currently, there are 186.88M common shares owned by the public and among those 144.65M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for TSHA have a consensus price objective of $5.72. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $2.00. The average price target is 47.2% above its recent price level and a downside to the estimated low will see the stock lose -51.0% over that period. But an upside of 62.25% will see the stock hit the forecast high price target while median target price for the stock is $6.00.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 281,217 shares. Insider sales of the common stock occurred on 6 occasions, with total insider shares sold totaling 549,095 shares.
Shares of Taysha Gene Therapies Inc. (NASDAQ: TSHA) opened at $3.45, down -$0.05 from a prior closing price of $3.50. However, the script later moved the day high at 3.4500, down -13.71%. The company’s stock has a 5-day price change of -16.34% and 266.06% over the past three months. TSHA shares are trading 33.63% year to date (YTD), with the 12-month market performance down to -11.70% lower. It has a 12-month low price of $0.50 and touched a high of $4.06 over the same period. TSHA has an average intraday trading volume of 4.60 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.62%, 101.07%, and 134.21% respectively.
Institutional ownership of Taysha Gene Therapies Inc. (NASDAQ: TSHA) shares accounts for 23.20% of the company’s 186.88M shares outstanding.
It has a market capitalization of $567.49M and a beta (3y monthly) value of -0.03. The earnings-per-share (ttm) stands at -$2.29. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.88% over the week and 18.36% over the month.
Analysts forecast that Taysha Gene Therapies Inc. (TSHA) will achieve an EPS of -$0.17 for the current quarter, -$0.14 for the next quarter and -$0.59 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.31 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.64 a year ago. Earnings per share for the fiscal year are expected to increase by 18.50%, and 24.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate Taysha Gene Therapies Inc. (TSHA) as a “Strong Buy” at a consensus score of 1.90. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 1 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TSHA, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on February 01, 2023, with the firm’s price target at $14-$1.50.